Tumor cells can achieve immunotherapy resistance through a variety of mechanisms, such as T cell depletion leading to PD-1 blockade treatment resistance, or induction of tumor cells expressing PD-L1 leading to adaptive immune resistance. This evidence concerns the gene CD274 and neoplasm.